Pfizer is reportedly looking to enhance its offer for Metsera, a company specializing in obesity treatments. This move highlights Pfizer's commitment to expanding its portfolio in the growing obesity market, which is increasingly important as more people seek effective weight management solutions. By potentially acquiring Metsera, Pfizer could strengthen its position in the pharmaceutical industry and provide innovative options for patients.